As of November 6, 2026, Passage BIO, Inc. is a publicly traded company (Nasdaq: PASG). The largest holder reporting an active stake on Schedule 13D is Lynx1 Capital Management LP, at 21%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Baselake Partners, LP (7.3%) (Schedule 13D, July 2, 2026).
Is this your company?
About to sign with, pay or invest in Passage BIO, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Passage BIO, Inc. a real, registered company?
- Passage BIO, Inc. files with the SEC under CIK 1787297 (its SEC filings).
- Its shares are listed under the ticker PASG on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Philadelphia, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Passage BIO, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-04-28).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Lynx1 Capital Management LP (filed 2026-07-02).
Who are Passage BIO, Inc.'s owners and officers?
Passage BIO, Inc.: incorporated in Delaware; business address in Philadelphia, Pennsylvania; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Vestal Point Capital, LP | 0% |
| Schedule 13D, 2026-07-02 | Lynx1 Capital Management LP | 21% |
| Schedule 13G, 2026-06-25 | Baselake Partners, LP | 7.3% |
| Schedule 13G/A, 2025-11-14 | Lynx1 Capital Management LP | 19.6% |
| Schedule 13D/A, 2025-07-24 | Orbimed Advisors LLC | 4.25% |
| Schedule 13D/A, 2025-07-21 | Orbimed Advisors LLC | 7.82% |
| Schedule 13D/A, 2025-07-09 | Orbimed Advisors LLC | 9.5% |
Questions about who owns Passage BIO, Inc.
Who owns Passage BIO, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Passage BIO, Inc.: Lynx1 Capital Management LP (21%, Schedule 13D, filed 2026-07-02) and Baselake Partners, LP (7.3%, Schedule 13G, filed 2026-06-25).
Who are the largest shareholders of Passage BIO, Inc.?
By the share each holder's latest filing reports, the largest holders of Passage BIO, Inc. on this page are Lynx1 Capital Management LP (21%) and Baselake Partners, LP (7.3%).
When did Lynx1 Capital Management LP buy into Passage BIO, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G/A, filed 2025-11-14, reporting 19.6%; its latest, Schedule 13D filed 2026-07-02, reports 21%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Passage BIO, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Passage BIO, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Passage BIO, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Passage BIO, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- OrbiMed Capital GP VII LLC, a 10% owner: 6,066,343 shares, held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-06-26).
- OrbiMed, a 10% owner: 6,066,343 shares, held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-06-26).
- Lynx1 Capital Management LP, a 10% owner: 673,759 shares (20.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-29).
- , a 10% owner: 673,759 shares (20.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-29).
- , the chief executive and president: 6,524 shares (0.20% of shares outstanding) (Form 4, 2026-01-12).
Shares outstanding: 3,217,810 as of 2026-08-05, from the company's latest SEC cover page.
How much has Passage BIO, Inc. raised?
No fundraising or offering filing from Passage BIO, Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-04-28).
Keep reading
More on Passage BIO, Inc. and the records around it.
Passage BIO, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Apr 2026
Companies that share a holder
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Generation Bio Co. (Feb 2026), Athira Pharma, Inc. (Feb 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/passage-bio